Skip to content

Category Archives: Food and Drug Administration

Emergent BioSolutions Awarded NIAID Contract That Increases Potential Funding to Over $58 Million for Advanced Development of Third Generation Anthrax Vaccine

Friday, September 10, 2010

New Contract Valued at up to $28.7 Million for Phase II Clinical Trial
ROCKVILLE, Md., Sep 01, 2010 –Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $28.7 million with the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institutes of [...]

Also filed in Biothrax, Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, Research and development, U.S. Food and Drug Administration | Tagged , , , , , | Comments (0)

Emergent BioSolutions Hosts Symposium for Biomedical Research Scholars

Monday, August 30, 2010

ROCKVILLE, Md., Aug 24, 2010 (BUSINESS WIRE) — Emergent BioSolutions Inc. (NYSE:EBS) today hosted “Looking Beyond the Bench,” a symposium organized for doctoral students enrolled in the NIH-Oxford-Cambridge Scholars Program. The symposium featured Emergent executives, who, based on their extensive experience in the biopharmaceutical industry, [...]

Also filed in Anthrax vaccines, Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, Infectious disease, Research and development, Scholars Program | Tagged , , , , , , , | Comments (0)

Emergent Revises Upward 2010 Financial Forecast

Tuesday, August 3, 2010

Company anticipates total revenues of $275 to $300 million and net income of $40 to $50 million
ROCKVILLE, MD, July 20, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it is revising upwards its 2010 annual guidance to now reflect anticipated total revenues of $275 to $300 million and net income of [...]

Also filed in Biothrax, Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri, Shareholder | Tagged , , , , , , , | Comments (0)

Emergent BioSolutions Awarded HHS Contract Valued at Up to $107 Million to Develop Large-Scale Manufacturing for BioThrax

Thursday, July 15, 2010

ROCKVILLE, Md., Jul 14, 2010
Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has signed a contract valued at up to $107 million with the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the Department of Health and Human Services (HHS), to develop and obtain regulatory approval for large-scale [...]

Also filed in Business, Chief Executive Officer, Emergent Bioslutions | Tagged , , , , , | Comments (0)

Emergent BioSolutions Completes Deliveries of BioThrax to Allied Foreign Governments

Wednesday, July 7, 2010

ROCKVILLE, MD, June 24, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) led by CEO Fuad El-Hibri,announced today that it has completed separate international sales and deliveries of BioThrax® (Anthrax Vaccine Adsorbed) to governments of several allied nations.  The company’s international sales efforts have resulted in these sales [...]

Also filed in Biothrax, Chief Executive Officer, Emergent Bioslutions, Fuad El-Hibri | Tagged , , , , , , | Comments (0)

Emergent BioSolutions Recognized as Biotechnology Firm of the Year by Tech Council of Maryland

Tuesday, May 18, 2010

ROCKVILLE, MD, May 13, 2010 – Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has been named Biotechnology Firm of the Year at the Tech Council of Maryland’s (TCM) Annual Tech Awards.  This award acknowledges the company that best exemplifies the spirit of Maryland’s biotechnology community as well as its presence and leadership within the [...]

Also filed in Chief Executive Officer, Fuad El-Hibri, Research and development, Tech Council of Maryland | Tagged , , , , , , | Comments (0)